PharmaNutra
€70.50Change from previous close: −0.98%Absolute change: −€0.70
At a glance
- Revenue growth
- +13.83%
- 2025 vs 2024
- Net income growth
- +20.44%
- 2025 vs 2024
- Net margin
- 15.0%
- 2024: 14.2%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 40.9 | 33.3 | 37.3 | 32.6 | 36.4 | — |
| Cost of revenue | 10.0 | 8.7 | 8.3 | 7.6 | 8.2 | — |
| Gross profit | 30.9 | 24.7 | 29.0 | 25.0 | 28.2 | — |
| Selling, general and administrative | 13.3 | 12.5 | 14.5 | 11.4 | 10.7 | — |
| Research and development | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | — |
| Operating income | 10.3 | 5.3 | 7.9 | 7.6 | 10.7 | — |
| EBIT | 10.1 | 5.4 | 8.3 | 7.7 | 10.5 | — |
| EBITDA | 11.0 | 6.3 | 9.2 | 8.8 | 11.4 | — |
| Interest expense | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | — |
| Pre-tax income | 9.9 | 5.3 | 8.2 | 7.6 | 10.4 | — |
| Income tax | 3.5 | 1.8 | 2.2 | 2.8 | 3.6 | — |
| Net income | 6.5 | 3.5 | 6.0 | 4.8 | 6.7 | — |
| Net income to common shareholders | 6.5 | 3.5 | 6.0 | 4.8 | 6.7 | — |
| Basic EPS | — | 0.36 | — | — | — | 0.25 |
| Diluted EPS | — | 0.36 | — | — | — | 0.25 |
| Average shares (basic) | — | 9.6 | — | — | — | 9.7 |
| Average shares (diluted) | — | 9.6 | — | — | — | 9.7 |